GLB1 and Alzheimer disease: The five biomarkers were enriched as follows, GLB1 was predominantly enriched in the lysosomal pathway, which was related to Parkinson’s disease, as well as in the pathways associated with sphingolipid metabolism and Alzheimer’s disease.